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S_nuary Between 1982 and 1990, 321 elderly patients (range 70-92 years, median age 77) with operable
breast cancer (TI in 219, T2 in 77, T3 in one and T4b in 24 patients) and clinically uninvolved axillary nodes
underwent surgery without axillary dissection and received adjuvant tamoxifen. All patients had surgery
performed under local anaesthesia. Tamoxifen was given after surgery at the dose of 20 mg daily, indefinitely.
With a median follow-up of 67 months (range 42-141), 17 patients developed local relapse, 14 ipsilateral
axillary recurrence, five ipsilateral breast cancer, five contralateral breast cancer, 13 second primary and 23
developed distant metastases. The cumulative probability of developing a local, axillary and distant recurrence
at 72 months was estimated to be 5.4%, 4.3% and 6.2%, respectively. Out of 244 patients who did not
develop any relapse, 83 (25.8%) died from intercurrent disease. The 72 month relapse-free survival rate was
76%. This experience suggests that elderly patients with small tumours without clinical axillary involvement
may be satisfactonrly treated with conservative surgery and tamoxifen. The importance of axillary dissection is
controversial owing to a high response rate to hormonal therapy and an increased death rate due to
concomitant diseases.
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Breast cancer is the most common malignancy occurring in
women. The incidence increases with age and approximately
30% of all new breast tumours occur in women over 70 years
of age (Silverberg et al., 1988; Decarli et al., 1989).
Guidelines for treating elderly patients are controversial
since co-morbid conditions and poor functional status do not
allow the application of clinical trials conducted in a younger
population. At present, there is no consensus on the optimal
treatment for breast cancer in this age group. Data from the
literature (Bradbeer et al., 1983; Allan et al., 1985; Cummings
et al., 1985; Margolese et al., 1989) suggest the use of tamox-
ifen either as primary treatment or as adjuvant therapy fol-
lowing surgery. Horobin et al. (1991) treated 113 patients
over the age of 70 years with tamoxifen alone. These patients
were followed for a minimum of 5 years and 60% failed to
respond, with a high number of cases requiring a second-line
treatment. Two randomised trials (Gazet et al., 1988; Robert-
son et al., 1988) comparing surgery with tamoxifen did not
find a difference in survival between the two groups but
locoregional control led to a better result in the surgically
treated patients. This led to the conclusion that optimum
treatment for elderly patients could include both surgery and
tamoxifen. A randomised study (Bates et al., 1991) compared
tamoxifen only with optimal surgery followed by adjuvant
tamoxifen. The overall survival after 3 years was similar
between the two groups but a statistically significant higher
locoregional relapse rate was reported in the group treated
by tamoxifen only.
The rationale of the present study was that non-rando-
mised clinical studies (Helleberg et al., 1982; Preece et al.,
1982; Allan et al., 1985) showed that tamoxifen as first-line
treatment was of value in a selected group of elderly breast
cancer patients. The question was whether surgery without
axillary dissection combined with tamoxifen in patients with
breast cancer and without clinical nodal involvement could
give the same results in terms of overall survival, disease-free
survival and quality of life compared with more radical
treatments.
In a previous paper (Martelli et al., 1993) analysing 151
elderly breast cancer patients treated with conservative
surgery and adjuvant tamoxifen we reported a remarkable
locoregional relapse-free survival rate at a median follow-up
time of 60 months. The aim of this paper is to re-examine the
safety of this procedure with a larger number of patients and
a longer follow-up.
Patent and methods
A retrospective chart review was conducted on 321 patients
aged 70 years or older with operable primary breast cancer
and clinically negative axillary nodes surgically treated at the
Istituto Tumori of Milan between 1982 and 1990.
The median age of patients at diagnosis was 77 years
(range 70-92). The diagnosis was basically made on clinical
and/or mammographic grounds; fine needle aspiration cyto-
logy was routinely performed before surgery. Physical
examination revealed that most tumours (74% of the cases)
were in the upper outer quadrant. Preoperative work-up
consisted of bone scan and chest radiograph.
Two hundred and nineteen patients (68.2%) had a tumour
size less than 2 cm (T1) according to the TNM system (Her-
manek et al., 1987), 77 (24%) a T2, 1 (0.3%) a T3 and 24
patients (7.5%) presented with a tumour infiltrating the skin
but not the underlying muscle (T4b). All patients had surgery
performed under local anaesthesia without axillary dissection;
298 underwent wide lumpectomy or quadrantectomy and 23
total mastectomy. The conservative surgical techniques have
been previously described (Veronesi et al., 1990; Galante et
al., 1992).
All patients underwent resection of the tumour with
removal of at least 2 cm of normal tissue to ensure a speci-
men with tumour-free margins. Patients with the margins of
resection in tumour tissue were excluded from the analysis,
since they were candidates for a re-excision or radiotherapy.
Independent of hormone receptor status, all patients
received indefinitely 20 mg tamoxifen daily from the time of
surgery. Tumour specimens were assayed for both oestrogen
receptor (ER) and progesterone receptor (PgR) levels by
using the dextran-coated charcoal Scatchard analysis. Recep-
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tor kvels were expressed in fmol mg-' cytosol protein.
Tumours with a receptor concentration < 10 or 25 fmol mg'
I
cytosol protein were consdered as ER negtive (ER-) or
PgR negative (PgR-), respectively, whereas tumours with
receptor content above such values were considered as recep-
tor positive (ER+, PgR+) (Ronchi et al., 1986).
Patients were followed up every 4 months for the first 3
years after surgery and every 6 months thereafter. Mammog-
raphy and chest radiograph were performed annually. One
hundred and seventy-two patients were followed for more
than 5 years and 25 for more than 10 years. The median
follow-up time was 67 months (range 42-141). The events
used as end points in the determination of relapse-free sur-
vival included first local recurrence of disease, axiflary and
distant metastases, recurce of tumour in the ipsilateral
breast after surgery, occurren of tumour in contralateral
breast and occurrce of a second primary tumour. As
previously described by Veronesi et al. (1990) we used the
following criteria to distinguish a local relapse from a new
primary ipsilateral tumour. Nodules localised in the skin
and/or the subcutaneous tissue and intramammary nodules
located within 3cm of the scar of previous surgery were
considered local relapses. Intramammary nodules located
more than 3 cm away from the site of the primary tumour
were considered as new primary ipsilateral tumours.
Patients with synchronous bilateral carcinomas or treated
for previous malignant tumours were excluded from the
analysis.
The product-limit method (Kaplan and Meier, 1958) was
used to estimate relapse free-survival curves. Local recur-
rence, axillary and distant metastases were considered
separately in the analysis. Since these events were not
independent, a competing risk approach was used (Kalbfleish
and Prentice, 1980). For each event the crude cumulative
incidence curves were obtained using a program developed
by Abbattista et al. (1992).
Resvlts
The predominant histological type was infiltrating ductal car-
cinoma (63.3%) and invasive lobular carcinoma accounted
for 19% ofthe cases. ER and PgR content was determined in
267 patients. Of these, there were 239 patients (89.5%) who
were ER', 190 (71.2%) who were PgR+ and 183 (69%) who
were positive to both tumour receptors. Overall, 92.1% of
the patients were receptor positive (ER or PgR) and 21
patients (7.9%) were ER- and PgR- (Table I).
Local failure in the breast occurred in 17 patients at a
median time from initial surgery of33 months (range 9-101).
The crude cumulative incidence of local relapse at 5 and 10
years from surgery was estimated to be 5.4% and 8.7%
respectively. In the TI group the local relapse rate at 72
months was 5.4% (12/219 patients). In all patients it was
possible to remove the tumour relapse with a new wide
resection. Four patients died from progression ofdisease, one
from a second primary and three from causes not related to
breast cancer.
Fourteen patients developed ipsilateral axillary recurrence
at a median time of 32 months (range 8-69) from surgery.
The crude cumulative incidence at 5 and 10 years was
estimated to be 4.3% and 5.9% respectively. In the TI group
the axillary recurrence rate at 72 months was 4.1% (9/219
patients). Eight patients were managed with radiotherapy,
five with axillary dissection and one patient had both
treatments. Four patients subsequently had further progress-
ion and died from disease and one patient from unrelated
conditions. Twenty-three patients developed disseminated
disease at a median time of 38 months (range 7-108) from
initial surgery. The crude cumulative incidence of distant
mtastascs at 5 and 10 years was estimated to be 6.2% and
13.4% respectively. Fifteen patients were treated with a
second-line hormonal treatment, four patients with radio-
therapy only and four patients had both treatments. Twenty-
one patients died from disease.
Five patients experienced new primary ipsilateral tumour
and five contralateral breast carcinoma. The median time
from initial surgery was 22 months (8-64 months) for
ipsilateral tumour and 25 months (6-39 months) for cont-
ralateral tumour. All patients with ipsilateral tumour were
treated with total mastectomy whereas wide resection was
performed on the five patients with contralateral breast
cancer.
Second primary tumours occurred in 13 patients (seven
bowel cancers, three gastric cancers, one renal cancer, one
vulvar cancer and one endometrial cancer) at a median time
from surgery of 37 months (23-127 months).
Total mastectomy was performed only in patients with a
larg tumour size (>3 cm) and with a concomitant very
small breast. The association of these two factors, large
tumour size and small breast, enabled us to perform surgery
under local anaesthesia without any complication and with
patients discharged on the day of surgery.
The distribution of site of recurre in relationship to
tumour size and ER and PgR status is shown in Table II.
Figure 1 shows the crude cumulative incidence of local,
axillary and distant relapse as a function of time on the total
series, and Figure 2 on 219 TI tumours. Two hundred and
forty-four patients did not have any recurrence and 83
(25.8%) died from diseases not related to breast cancer.
Cardiovascular diseases were the most common cause of
death. The overall 72 month relapse-free survival rate was
76% with a 95% confidence interval (0.75-0.89) (Figure 3).
The data reported here seem to confirm that a strategy
consisting in breast conservative surgery and adjuvant
tamoxifen may yield results in terms of locoregional relapse
rate equivalent to those obtained with more radical surgical
approaches (Robertson et al., 1992). The critical issue is
whether axillary dissection may be safely omitted in elderly
patients with primary breast cancer and clinically negative
axillary nodes.
A randomised clinical trial (Fisher et al., 1985) compared,
in patients with breast cancer and clnically negative axillary
nodes, radical mastectomy with total mastectomy plus
delayed axillary dissection only if nodes became clinically
involved. The results at 10 years showed that of the 40% of
patients in the group without axillary dissection expected to
Table I Clinical characteristics of321 elderly breast cancer patients
No. ofcases %
Median age 77 years (range 70-92)
Patooia tuour size
pTI
pT2
pT3
pT4b
Hitokoical type
Inf i~at du a carcinoma
Invasive lobular carcinoma
Intraductal carcinoma
Mncinous carcinoma
Paplary carcioma
Tubular carcinoma
Modullary carcinoma
In situ lobular carcinoma
Receptor status (available in 267 cases)
ER+ PgR+
ER+ PgR-
ER- PgR+
ER- PgR-
219
77
1
24
203
60
18
18
10
6
3
3
68.2
24.0
0.3
7.5
63.3
18.7
5.6
5.6
3.1
1.9
0.9
0.9
183 68.5
56 21.0
7 2.6
21 7.9Surgy wbsdaxEy dc5o - pamnbozl i edely hrn ra p-u*s
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Figre 3 Relapse-free survival; 321 elderly breast cancer patients
without axillary dissection.
have histologically postive nodes, only 18% required subse-
quent axillary dissection for the development of clinical
involvement. This study also indicated that the overall sur-
vival is similar if axillary dissection is performed simul-
taneously with removal of primary breast cancer or at clinical
evidence of axillary relapse. In the present series 14 of the
321 patients (4.3%) experienced an axillary relapse after a
median follow-up time of 67 months. The selection of
patients without clinical nodal involvement, the high rate of
T1 tumours and the possibility that an anti-oestrogenic
intervention (i.e. tamoxifen having an inhibitory effect on
locoregional tumour growth) may account for this low
relapse rate. It is reasonable to think that an older woman
with TlNO breast cancer after a combined therapy of surgery
and tamoxifen is more likely to die from intercurrent disease
than from progression of breast cancer.
Patients with negative receptors generally considered as
being of poor prognosis did not have a higher number of
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distant relapses compared with ER' patients. Moreover, no
patient with an ER- tumour had an axillary relapse after a
median follow-up tim of 67 months, whereas local failure
resulted more frequently in ER- patients (25% vs 3.3% in
ER+ patients). These data may indicate that ER- tumours
determine a higher rate of local relapse without affecting
overall survival and that a subgroup of ER- and PgR- or
ER- and PgR+ patients respond to an anti-oestrogenic
therapy.
Some authors (Allan et al., 1985; Margolese et al., 1989)
suggeted tamoxifen only as an alternative to surgery m
elderly patients with breast cancer but controlled clinical
trials (Gazet et al., 1988; Robertson et al., 1988; Bates et al.,
1991) showed that pimary tamoxifen was inadequate to
control locoregional disease in more than 40% of the cases.
We believe that only patients unfit for surgery or who deine
a surgical intervention may be treated by tamoxifen alone as
first-line treatment. Cinical evidence from randomised trials
suggests that there is an inreased risk of women developing
endometrial cancer if tamoxifen is taken at a dose of
20mgdaily for long periods (Nayfield et al., 1991; Catherino
et al., 1993). In this study we did not observe an ieased
risk of endometrial or other types of second ancers related
to this age group. Only one woman experienced an endomet-
rial cancer 52 months after breast surgery. We point out that
no patient in follow-up had a rouine periodical
gynaecological assesment such as pevic ultrasonography or
hysteroscopy.
Given the role of surgery as primary therapy another issue
has to be addressed. Is wide lumpectomy alone adequate
therapy or should radiotherapy be administered after breast-
preserving surgery? A recent controlled clinical trial (Veronesi
et al., 1993) has challenged the usefulss of post-surgical
radiotherapy in post-menopausal patients treated with con-
servative surgery. That study compared quadrantectomy vs
quadrantectomy plus radiotherapy in patients with breast
cancer size<2.5cm. and showed, in patients older than 55
years, a local relapse rate of 3.8% in the group without
radiotherapy after a median follow-up of 39 months. The
results of this study are similar to those of the present paper
where, with a median follow-up of 67 months, the local
relapse rate after conservative surgery and tamoxifen was
5.3%. The data of these two reports suggests that conser-
vative surgery alone in post-menopausal patients with TI
breast cancer may yield an acceptable local control. Other
studies (Gazet et al., 1988; Reed et al., 1989; Bates et al.,
1991; Fisher et al., 1991) reported a higher rate of local
relapse after breast-preerving surgery without adjuvant
radiotherapy. The disagreement may be expained by the
diference in surgial procedures. Wide lumpectomy or
quadrantectomy consists in a more extensive excision, com-
pared with humpectomy, removing at kast 2 cm of normal
breast tissue around the tumour with the corresponding por-
tion of overying skin.
It is very difficult to predict the risk of local recurrmce m
patients with tumours in macroscopically clear margins. The
presence of an extensive intraductal component is generally
considered as an important predictor of the risk of local
relapse (Harris et al., 1985). Another explanation may be the
presnce in the breast of cancer cells beyond the negative
margns of resection and such cases are not identified by the
pathologist
All these data seem to indicate a new operative model for
the treatment of TINO breast cancer in elderly patients: i.e.
conservative surgery without axillary distion, without
post-operative radiotherapy followed by adjuvant tamoxifen.
The advantages of conservative surgery without axillary
dissection are numerous. Firstly, the omission of axillary
learance would avoid the morbidity linked to axillary
surgry inding ipairt of arm motion and lym-
phoedema. Secondly, wide lumpectomy or quadrantectomy
without axillary disection can be performed in a day hos-
pital regimn under local ana a and thirdly, it gives the
possibility of reducing the high social costs for age-related
cancers.
The best way to resolve the issue of whether elderly
patients with TI breast cancer and without clinical axillary
involvement should be recommended surgery with or without
axillary dissection would be a randomised prospective trial.
Such a trial would have the aim of verifying the necessity of
axillary dissection and the impact on disease-free survival.
In conclusion, the treatment ofearly stage breast ancer in
elderly patients has to be re-evaluated in the near future,
perhaps resticting axillary node dissection to those patients
with chnically involved nodes.
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